Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use

References

• . Institute of Medicine (IOM). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington. DC: The National Academies Press; 2011
   Google Scholar
• . US Food and Drug Administration (FDA). FDA acts to reduce harm from opioid drugs. 2011. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm251830.htm. Updated April 2013. Accessed April 29, 2013
   Google Scholar
• . Chou R, Fanciullo GJ, Fine PG, ; American Pain Society-American Academy of Pain Medicine Opioids Guideline Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130
   PubMed Web of Science ®Google Scholar
• . The Management of Opioid Therapy for Chronic Pain Working Group. VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. Washington, DC: Department of Veterans Affairs, Department of Defense; 2010
   Google Scholar
• . Manchikanti L, Abdi S, Atluri S, ; American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2—guidance. Pain Physician. 2012;15 ( 3 suppl):S67–S116
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Abdi S, Atluri S, ; American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I—evidence assessment. Pain Physician. 2012;15( 3 suppl):S1–S65
   Google Scholar
• . Utah Department of Health. Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. Salt Lake City, UT: Utah Department of Health; 2009
   Google Scholar
• . Webster LR. Considering the risks of benzodiazepines and opioids together. Pain Med. 2010;11(6):801–802
   PubMedGoogle Scholar
• . Skurtveit S, Furu K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids—a follow-up study of 17,074 men and women. Pain Med. 2010;11(6):805–814
   PubMedGoogle Scholar
• . World Health Organization (WHO) Programme on Substance Abuse. Rational Use of Benzodiazepines. Geneva, Switzerland: WHO; 1996. www.who.int/iris/handle/10665/65947. Accessed April 30, 2013
   Google Scholar
• . National Opioid Use Guideline Group (NOUGG). Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Part B: Recommendations for practice. Version 5.6. 2010. http://nationalpaincentre.mcmaster.ca/opioid/. Published April 30, 2010. Accessed April 30, 2013
   Google Scholar
• . Substance Abuse and Mental Health Services Administration (SAMHSA). The TEDS Report: Sub stance Abuse Treatment Admissions for Abuse of Benzodiazepines. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2011
   Google Scholar
• . Substance Abuse and Mental Health Services Administration (SAMHSA). The TEDS Report: Admissions Reporting Benzodiazepine and Narcotic Pain Reliever Abuse at Treatment Entry. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2012
   Google Scholar
• . Substance Abuse and Mental Health Services Administration (SAMHSA). Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Rockville, MD: SAMHSA; 2012
   Google Scholar
• . Substance Abuse and Mental Health Services Administration (SAMHSA). Drug Abuse Warning Network, 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Center for Behavioral Health Statistics and Quality, SAMHSA; 2012
   Google Scholar
• . Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999–2009 [published online ahead of print January 4, 2013]. Drug Alcohol Depend
   Google Scholar
• . Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–659
   PubMed Web of Science ®Google Scholar
• . Johnson E. Utah Drug Overdose Mortality: Findings From Interview With Family and Friends of Utah Residents Aged 13 and Older Who Died of a Drug Overdose Between October 26, 2008 and October 25, 2009. Salt Lake City, UT: Utah Department of Health; 2009
   Google Scholar
• . Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int. 2001;121(1–2):65–69
   PubMed Web of Science ®Google Scholar
• . Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction. 2004;99(8):978–988
   PubMedGoogle Scholar
• . Ernst E, Bartu A, Popescu A, Ileutt KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993–99. Aust N Z J Public Health. 2002;26(4):364–370
   PubMed Web of Science ®Google Scholar
• . Wolf BC, Lavezzi WA, Sullivan LM, Flannagan LM. Methadone-related deaths in Palm Beach County. J Forensic Sci. 2004;49(2):375–378
   PubMedGoogle Scholar
• . Oliver P, Keen J. Concomitant drugs of misuse and drug using behaviours associated with fatal opiate-related poisonings in Sheffield, UK, 1997–2000. Addiction. 2003;98(2):191–197
   PubMed Web of Science ®Google Scholar
• . Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1–2):8–18
   PubMed Web of Science ®Google Scholar
• . White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961–972
   PubMed Web of Science ®Google Scholar
• . Jarzyna D, Jungquist CR, Pasero C, . American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs. 2011;12(3):118–145.e10
   PubMed Web of Science ®Google Scholar
• . Chen KW, Berger CC, Forde DP, D'Adamo C, Weintraub E, Gandhi D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry. 2011;11:90
   PubMed Web of Science ®Google Scholar
• . Farre M, Teran MT, Roset PN, Mas M, Torrens M, Cami J. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology (Berl). 1998;140(4):486–495
   PubMed Web of Science ®Google Scholar
• . Spiga R, Huang DB, Meisch RA, Grabowski J. Human methadone self-administration: effects of diazepam pretreatment. Exp Clin Psychopharmacol. 2001;9(1):40–46
   PubMed Web of Science ®Google Scholar
• . Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend. 2007;91(2–3):187–194
   PubMed Web of Science ®Google Scholar
• . Preston KL, Griffiths RR, Stitzer ML, Bigelow GE, Liebson IA. Diazepam and methadone interactions in methadone maintenance. Clin Pharmacol Ther. 1984;36(4):534–541
   PubMed Web of Science ®Google Scholar
• . Hou RH, Scaife J, Freeman C, Langley RW, Szabadi E, Bradshaw CM. Relationship between sedation and pupillary function: comparison of diazepam and diphenhydramine. Br J Clin Pharmacol. 2006;61(6):752–760
   PubMedGoogle Scholar
• . Bailey PL, Pace NL, Ashburn MA, Moll JW, East KA, Stanley TH. Frequent hypoxemia and apnea after sedation with midazolam and fentanyl. Anesthesiology. 1990;73(5):826–830
   PubMed Web of Science ®Google Scholar
• . Faroqui MH, Cole M, Curran J. Buprenorphine, benzodiazepines and respiratory depression. Anaesthesia. 1983;38(10):1002–1003
   PubMedGoogle Scholar
• . Nemeroff CB, De Vane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3):311–320
   PubMed Web of Science ®Google Scholar
• . Altamura AC, Moliterno D, Paletta S, Maffini M, Mauri MC, Bareggi S. Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol. 2013;9(4):423–440
   PubMed Web of Science ®Google Scholar
• . Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–624
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration (FDA). Safety information for Palladone (hydromorphone hydrochloride). 2005. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucml52047.htm. Updated June 19, 2009. Accessed March 18, 2013
   Google Scholar
• . Fields E. History of Modified-Release Morphine and Opioid/Antagonist Combinations. 2008. http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4395s2-00-index.htm. Updated November 21, 2008. Accessed May 8, 2013
   Google Scholar
• . Carson S, Thakurta S, Low A, Smith B, Chou R. Drug Class Review: Long-Acting Opioid Analgesics. Final Update 6 Report. Portland, OR: Oregon Health and Science University; 2011. http://www.ncbi.nlm.nih.gov/books/NBK62335/. Accessed June 27, 2013
   Google Scholar
• . Fiske WD, Jobes J, Xiang Q, Chang SC, Benedek IH. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets. J Pain. 2012;13(1):90–99
   PubMed Web of Science ®Google Scholar
• . Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin. 2008;24(1):297–305
   PubMed Web of Science ®Google Scholar
• . Johnson FK, Ciric S, Boudriau S, Kisicki J, Stauffer J. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol. 2012;52(5):747–756
   PubMed Web of Science ®Google Scholar
• . Hakkinen M, Launiainen T, Vuori E, Ojanpera I. Comparison of fatal poisonings by prescription opioids. Forensic Sci Int. 2012;222(1–3):327–331
   PubMedGoogle Scholar
• . Webster LR, Cochella S, Dasgupta N, . An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12( suppl 2):S26–S35
   PubMed Web of Science ®Google Scholar
• . Ali NA Marshall RW, Allen EM, Graham DF, Richens A. Comparison of the effects of therapeutic doses of meptazinol and a dextropropoxyphene/paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements. Br J Clin Pharmacol. 1985;20(6):631–637
   PubMedGoogle Scholar
• . Zacny JP, Gutierrez S. Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. Psychopharmacology (Berl). 2011;218(3):471–481
   PubMed Web of Science ®Google Scholar
• . Hermos JA, Young MM, Gagnon DR, Fiore LD. Characterizations of long-term oxycodone/acetaminophen prescriptions in veteran patients. Arch Intern Med. 2004;164(21):2361–2366
   PubMedGoogle Scholar
• . Dunn KM, Saunders KW, Rutter CM, . Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92
   PubMed Web of Science ®Google Scholar
• . Bachs LC, Bramness JG, Engeland A, Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Norsk Epidemiologi. 2008;18(2):185–190
   Google Scholar
• . King SA, Strain JJ. Benzodiazepine use by chronic pain patients. Clin J Pain. 1990;6(2):143–147
   PubMed Web of Science ®Google Scholar
• . Saunders KW, Von Korff M, Campbell CI, . Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors. J Pain. 2012;13(3):266–275
   PubMed Web of Science ®Google Scholar
• . Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573–582
   PubMed Web of Science ®Google Scholar
• . Saffier K, Colombo C, Brown D, Mundt MP, Fleming MF. Addiction Severity Index in a chronic pain sample receiving opioid therapy. J Subst Abuse Treat. 2007;33(3):303–311
   PubMed Web of Science ®Google Scholar
• . UK Department of Health. Drinkers can underestimate alcohol habits [press release]. 2013. https://www.gov.uk/government/news/drinkers-can-underestimate-alcohol-habits. Published February 7, 2013. Accessed April 27, 2013
   Google Scholar
• . Friedmann PD. Clinical practice. Alcohol use in adults. N Engl J Med. 2013;368(4):365–373
   PubMed Web of Science ®Google Scholar
• . Meiler A, Mino A, Chatton A, Broers B. Benzodiazepine use in a methadone maintenance programme: patient characteristics and the physician's dilemma. Schweiz Arch Neurol Psychiatr. 2005;156: 310–317
   Google Scholar
• . Rooney S, Kelly G, Bamford L, Sloan D, O'Connor JJ. Co-abuse of opiates and benzodiazepines. Ir J Med Sci. 1999;168(1):36–41
   PubMedGoogle Scholar
• . Ross J, Darke S. The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction. 2000;95(12):1785–1793
   PubMed Web of Science ®Google Scholar
• . Eiroa-Orosa FJ, Haasen C, Verthein U, Dilg C, Schafer I, Reimer J. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend. 2010;112(3):226–233
   PubMedGoogle Scholar
• . Dhalla S, Kopec JA. The CAGE questionnaire for alcohol misuse: a review of reliability and validity studies. Clin Invest Med. 2007;30(1):33–41
   PubMed Web of Science ®Google Scholar
• . Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789–1795
   PubMed Web of Science ®Google Scholar
• . Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;24(7):783–788
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Manchukonda R, Pampati V, . Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9(2):123–129
   PubMedGoogle Scholar
• . Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and best practices. Pain Physician. 2012;15( 3 suppl):ES119–ES133
   PubMed Web of Science ®Google Scholar
• . Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15( 3 suppl):ES67–ES92
   PubMed Web of Science ®Google Scholar
• . Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med. 2004;5(3):309–324
   PubMedGoogle Scholar
• . Trescot AM, Helm S, Hansen H, . Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11( 2 suppl):S5–S62
   PubMed Web of Science ®Google Scholar
• . Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician. 2009;12(3):507–515
   PubMed Web of Science ®Google Scholar
• . Alliance of States with Prescription Monitoring Programs (ASPMP) Web site, http://www.pmpalliance.org/. Accessed March 27, 2013
   Google Scholar
• . Michna E, Jamison RN, Pham LD, . Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of 24 abnormal findings. Clin J Pain. 2007;23(2):173–179
   PubMed Web of Science ®Google Scholar
• . Gourlay DL, Heit HA. Universal precautions revisited: managing the inherited pain patient. Pain Med. 2009;10( suppl 2):S115–S123
   PubMed Web of Science ®Google Scholar
• . Centers for Medicare and Medicaid Services (CMS). Medicare Coverage Database. CMS Web site, http://www.cms.gov/medicare-coverage-database. Accessed April 30, 2013
   Google Scholar
• . Peppin JF, Passik SD, Couto JE, . Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012;13(7):886–896
   PubMed Web of Science ®Google Scholar
• . Christo PJ, Manchikanti L, Ruan X, . Urine drug testing in chronic pain. Pain Physician. 2011;14(2):123–143
   PubMed Web of Science ®Google Scholar
• . Substance Abuse and Mental Health Services Administration (SAMHSA). Clinical Drug Testing in Primary Care. Rockville, MD: SAMHSA; 2012. Technical Assistance Publication (TAP) 32. HHS publication (SMA) 12–4668
   Google Scholar
• . Helander A, Bottcher M, Fehr C, Dahmen N, Beck O. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol. 2009;44(1):55–61
   PubMed Web of Science ®Google Scholar
• . Glover SJ, Allen KR. Measurement of benzodiazepines in urine by liquid chromatography-tandem mass spectrometry: confirmation of samples screened by immunoassay. Ann Clin Biochem. 2010;47(pt 2):111–117
   PubMedGoogle Scholar
• . Walsham NE, Sherwood RA. Ethyl glucuronide. Ann Clin Biochem. 2012;49(pt 2):110–117
   PubMed Web of Science ®Google Scholar
• . Wurst FM, Vogel R, Jachau K, . Ethyl glucuronide discloses recent covert alcohol use not detected by standard testing in forensic psychiatric inpatients. Alcohol Clin Exp Res. 2003;27(3):471–476
   PubMed Web of Science ®Google Scholar
• . Hoiseth G, Yttredal B, Karinen R, Gjerde H, Christophersen A. Levels of ethyl glucuronide and ethyl sulfate in oral fluid, blood, and urine after use of mouthwash and ingestion of nonalcoholic wine. J Anal Toxicol. 2010;34(2):84–88
   PubMedGoogle Scholar
• . Helander A, Olsson I, Dahl H. Postcollection synthesis of ethyl glucuronide by bacteria in urine may cause false identification of alcohol consumption. Clin Chem. 2007;53(10):1855–1857
   PubMed Web of Science ®Google Scholar
• . Schloegl H, Dresen S, Spaczynski K, Stoertzel M, Wurst FM, Weinmann W. Stability of ethyl glucuronide in urine, post-mortem tissue and blood samples. Int J Legal Med. 2006;120(2):83–88
   PubMedGoogle Scholar
• . Kelly AT, Mozayani A. An overview of alcohol testing and interpretation in the 21st century. J Pharm Pract. 2012;25(1):30–36
   PubMedGoogle Scholar
• . Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66–76
   PubMed Web of Science ®Google Scholar
• . Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain. 2002;18( 4 suppl):S76–S82
   PubMed Web of Science ®Google Scholar
• . Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99(1–3):280–295
   PubMed Web of Science ®Google Scholar
• . Jonas DE, Garbutt JC, Amick HR, . Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2012;157(9):645–654
   PubMed Web of Science ®Google Scholar
• . Khong E, Sim MG, Hulse G. Benzodiazepine dependence. Aust Fam Physician. 2004;33(11):923–926
   PubMedGoogle Scholar
• . Otte C. Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues Clin Neurosci. 2011;13(4):413–421
   PubMedGoogle Scholar
• . Cottraux J. Nonpharmacological treatments for anxiety disorders. Dialogues Clin Neurosci. 2002;4(3):305–319
   PubMedGoogle Scholar
• . Kraus ML, Alford DP, Kotz MM, ; American Society of Addiction Medicine. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5(4):254–263
   PubMed Web of Science ®Google Scholar
• . Substance Abuse and Mental Health Services Administration (SAMHSA). Screening, Brief Intervention, and Referral to Treatment (SBIRT) in behavioral healthcare. 2011. http://www.samhsa.gov/prevention/sbirt/. Published April 1, 2011. Accessed April 30, 2013
   Google Scholar